Traws Pharma, Inc. announced that it has entered into a share purchase agreement to issue 496,935 common shares and 1,578.2120 series C preferred stock for the aggregate gross proceeds of $14,000,000 on April 1, 2024. The transaction included participation from new investors Orbimed Private Investments VIII, LP, managed by, OrbiMed Advisors LLC and TPAV, LLC, managed by, Torrey Pines. The common shares issuable upon conversion of the series C preferred stock issued in the private financing shall be subject to stockholder approval in compliance with the rules of the NASDAQ Stock Market.

Each share of Series C Preferred Stock is convertible into 10,000 shares of Common Stock.